New publication 📝 We highlight key strategies for CRS risk mitigation and prophylaxis, recognition and monitoring, and management during BsAb treatment for RRMM in community practice.
Learn more: https://t.co/RtFiAW043X
#myeloma#mmsm#MedNews#MedEd
You're invited! Register now to join the global myeloma community in Glasgow for the premier meeting in myeloma research and care. #IMS26 🌎➡️https://t.co/km3dXW9DcZ
📌Abstract submissions are open for the 10th Nursing & Allied Health Symposium and the 23rd IMS Annual Meeting! Get started today: https://t.co/JlyBySTyGw #IMS26
Join us for the 23rd IMS Annual Meeting in Glasgow, Scotland September 23-26. Registration and abstract submission are now open! Check out this link for more details ➡️ https://t.co/uO20TXubyd #IMS26
4/ Thank you to all physicians around world who completed survey and to @BrJHaem reviewers!
Special thanks to my partner-in-crime @GKaurMD on this, @VincentRK for encouraging us to push this to finish line, and our 🇦🇺🇮🇳🇨🇦🇺🇸 co-authors!
Link to article:
https://t.co/8XBeUodNUn
It has been great to visit beautiful Australia. Thank you Professor Joy Ho for welcoming me to Royal Prince Alfred and for showing me around beautiful Sydney!
The myeloma community is close knit and colleagues are dear friends.
Primary IVIG PPx with BCMA bsAbs in myeloma #MMsm: now in more guidelines!
New CLML expert recs by @paurotero et al. Many nice pearls about SUD & dosing.
Also this 👇🏼 Withholding IVIG based on IgG < 400 mg/dL (4 g/L) is playing with fire, so - if needed - use higher threshold.
Agree, prospective work esp as we now use multi-agent regimens and have tools to measure steroid toxicities in MM https://t.co/oipFaFmQHO
In my 35yr clinical MM nursing exp - pts are adversely impacted more by dexa than any other agent/morbidity. We can improve this
Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis: corticosteroid-sparing regimens warrant prospective investigation across the gamut of plasma cell disorders @RahulBanerjeeMD@vsanchorawala@jmikhaelmd https://t.co/1w4Yd0Yo00
Our practice is overdue for clear guidance on #downwithdex to further reduce burden of toxicities associated with long term MM therapies - we hope the JCO paper will fuel interest in dexa sparing strategies in future clinical trials and practice
@OncBrothers@BijoyTelivala Agreed with both of you! IFM 2017-03 is leading the way here - with SC dara in any line including SMM, I ditch all pre-meds after 2 cycles including dex.
@jmikhaelmd@Bethfaiman@MMKingT and I actually have a JCO paper about #downwithdex coming out next week - more soon!
Our thoughts are with the injured, their families and those who have lost loved ones because of this tragedy.
On Sunday we issued several life-threatening orders for O- blood, in the wake of the incident at Bondi.
Please make an appointment if you can. https://t.co/dGC0V7Cdsi
@smbenlazar Costs aside - deliverability will take creating realistic expectations & focussed supportive care - phys/psych | fitness, resilience, time tox etc